MGMT and glioblastoma: In conclusion, though phase III randomised studies have shown improved survival in elderly patients with MGMT promoter methylation treated with temozolomide, at present there is insufficient evidence to recommend temozolomide as a monotherapy in elderly GBM patients who are fit for multimodality treatment as there have been no randomised trials comparing standard chemoradiotherapy to temozolomide monotherapy alone.